Global Influenza Drug Market
Tamaño del mercado en miles de millones de dólares
Tasa de crecimiento anual compuesta (CAGR) :
% 
 Período de pronóstico |
2023 –2030 |
 Tamaño del mercado (año base) |
USD 960.55 Billion |
 Tamaño del mercado (año de pronóstico) |
USD 1,084.07 Billion |
 Tasa de crecimiento anual compuesta (CAGR) |
% |
| Jugadoras de los principales mercados |
|
>Mercado mundial de medicamentos contra la influenza, por tipo (influenza A, influenza B e influenza C), tratamiento (vacunas y medicamentos), vía de administración (oral, intramuscular, intradérmica, intranasal e intravenosa), edad (pediatría y adultos), usuario final (hospitales y atención domiciliaria), canal de distribución (licitaciones directas y ventas minoristas): tendencias de la industria y pronóstico hasta 2031.
Análisis y tamaño del mercado de medicamentos contra la gripe
Un factor que impulsa el mercado mundial de medicamentos contra la gripe es la creciente concienciación sobre la gripe y sus posibles complicaciones, que está impulsando una mayor demanda de soluciones preventivas y terapéuticas. Sin embargo, un desafío notable es la presencia de versiones genéricas de medicamentos contra la gripe, que genera presiones sobre los precios y una posible reducción de los márgenes de beneficio de los fabricantes. A pesar de ello, existe una oportunidad en el desarrollo de medicamentos nuevos y más eficaces para hacer frente a las nuevas cepas del virus de la gripe, lo que ofrece una ventaja competitiva. No obstante, un desafío persistente es la necesidad de realizar esfuerzos de investigación y desarrollo continuos para adaptarse a la naturaleza cambiante del virus de la gripe y su tendencia a desarrollar resistencia a los tratamientos actuales.
Data Bridge Market Research analiza que el mercado mundial de medicamentos contra la gripe está creciendo con una CAGR del 6,5% en el período de pronóstico de 2024 a 2031 y se espera que alcance los USD 14,22 mil millones para 2031 desde USD 8,73 mil millones en 2023. Se espera que la creciente prevalencia de varios tipos de cáncer impulse la expansión del mercado.
|
Métrica del informe |
Detalles |
|
Período de pronóstico |
2024 a 2031 |
|
Año base |
2023 |
|
Años históricos |
2022 (Personalizable 2015-2020) |
|
Unidades cuantitativas |
Ingresos en millones de USD |
|
Segmentos cubiertos |
Tipo (gripe A, influenza B e influenza C), tratamiento (vacunas, medicamentos), vía de administración (oral, intramuscular, intradérmica, intranasal e intravenosa), edad (pediatría y adultos), usuario final (hospitales y atención domiciliaria), canal de distribución (licitación directa y ventas minoristas) |
|
Países cubiertos |
EE. UU., Canadá, México, Alemania, Italia, Reino Unido, Francia, Suiza, España, Rusia, Turquía, Bélgica, Países Bajos, Resto de Europa, China, India, Corea del Sur, Japón, Tailandia, Australia, Singapur, Indonesia, Malasia, Filipinas, Resto de Asia-Pacífico, Brasil, Argentina, Resto de Sudamérica, Arabia Saudita, Emiratos Árabes Unidos, Sudáfrica, Egipto, Israel y Resto de Medio Oriente y África |
|
Actores del mercado cubiertos |
GSK plc., Sanofi SA, CSL, Astrazeneca Plc, F. Hoffmann-La Roche Ltd, Viatris Inc., Abbott, Amneal Pharmaceuticals LLC., AbbVie Inc BioCryst Pharmaceutucals, Inc., Lupin, Zydus Pharmaceuticals, Inc., Macleods Pharmaceuticals Ltd., Viatris Inc., DAIICHI SANKYO COMPANY, LIMITED, Cipla Inc., Shionogi & Co., Ltd., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, NATCO Pharma Limited y Alvogen, entre otros. |
Definición de mercado
Los medicamentos contra la gripe son medicamentos creados para prevenir o tratar la gripe, una enfermedad respiratoria contagiosa. Incluyen medicamentos antivirales que se centran en el virus de la gripe en sí, así como medicamentos que ayudan a aliviar síntomas como fiebre, tos y congestión. Estos medicamentos son esenciales para controlar y reducir el impacto de los brotes de gripe, en particular durante épocas de transmisión generalizada o pandemias.
Dinámica del mercado mundial de medicamentos contra la gripe
En esta sección se aborda la comprensión de los factores impulsores, las ventajas, las oportunidades, las limitaciones y los desafíos del mercado. Todo esto se analiza en detalle a continuación:
Conductores
- Aumento de la tasa de prevalencia de la gripe
El mercado mundial de medicamentos contra la gripe está experimentando un importante impulso en su crecimiento debido a la creciente prevalencia de infecciones virales en todo el mundo. La tasa de prevalencia de la gripe sigue subrayando la necesidad crítica de avances en los medicamentos y vacunas contra la gripe. Con la aparición de diversas cepas y la amenaza constante de brotes estacionales, el mercado de medicamentos contra la gripe ha experimentado un crecimiento significativo. Entre los principales contribuyentes a esta expansión se encuentran el desarrollo y la adopción de vacunas con diferentes formulaciones de valencia. Las vacunas cuadrivalentes, por ejemplo, ofrecen protección contra cuatro cepas de gripe diferentes, lo que proporciona una cobertura más amplia en comparación con sus contrapartes trivalentes. Estas vacunas están disponibles en varias formas, incluidas la inyección y el aerosol nasal, que atienden diferentes preferencias y necesidades. La inyección cuadrivalente ofrece un método de inmunización conveniente y eficaz, en particular para las personas que buscan una protección rápida y confiable contra la gripe. Por otro lado, la formulación en aerosol nasal proporciona una opción alternativa, especialmente para quienes son reacios a las agujas. Además, las vacunas trivalentes siguen siendo esenciales en regiones donde prevalecen cepas específicas, lo que garantiza una protección específica contra los virus de la gripe en circulación. Al incorporar diversas opciones de valencia, incluidas formulaciones cuadrivalentes y trivalentes, el mercado de medicamentos y vacunas contra la influenza continúa evolucionando, ofreciendo soluciones integrales para combatir la propagación de la enfermedad y mitigar su impacto en la salud pública.
Por ejemplo,
- En octubre de 2023, según el artículo publicado por la OMS, la gripe estacional representa una importante carga sanitaria mundial, con aproximadamente mil millones de casos notificados anualmente, incluidos entre 3 y 5 millones de casos de enfermedad grave. El impacto es especialmente grave en los países en desarrollo, donde el 99% de las muertes en niños menores de 5 años se deben a infecciones de las vías bajas relacionadas con la gripe y debido a las cuales se producen entre 290.000 y 650.000 muertes anuales, lo que pone de relieve la gravedad de la enfermedad y sus posibles consecuencias, especialmente en las poblaciones vulnerables.
- En noviembre de 2021, según el artículo publicado por el NCBI, las epidemias de gripe suponen una importante amenaza para la salud pública, ya que provocan entre 290.000 y 650.000 muertes en todo el mundo cada año. Sin embargo, el coste de las pandemias de gripe puede ser aún más devastador. La pandemia A(H1N1) de 1918-1919, también conocida como gripe española, es un duro recordatorio de la posible gravedad de los brotes de gripe. Esta pandemia provocó entre 20 y 50 millones de muertes en todo el mundo, lo que la convierte en una de las pandemias más mortíferas de la historia.
En conclusión, el desarrollo y la utilización de medicamentos y vacunas antigripales multivalentes, como las formulaciones tetravalentes y los métodos de administración alternativos como los aerosoles nasales, son pasos cruciales para controlar eficazmente la prevalencia de la gripe. Este enfoque multifacético no solo mejora la cobertura de vacunación, sino que también contribuye significativamente al crecimiento del mercado de medicamentos y vacunas antigripales. Por lo tanto, a medida que la industria sanitaria mundial sigue priorizando la salud, la creciente prevalencia de infecciones virales actúa como catalizador para los avances en las modalidades de tratamiento, lo que contribuye al crecimiento sostenido del mercado mundial de la gripe.
- Iniciativas gubernamentales y programas de vacunación
El aumento de las iniciativas gubernamentales y la ampliación de los programas de vacunación desempeñan un papel fundamental en el impulso del crecimiento del mercado de medicamentos contra la gripe, ya que fomentan la demanda estimulante. A medida que los gobiernos de todo el mundo priorizan la salud pública a través de estrategias integrales de inmunización, las empresas farmacéuticas especializadas en medicamentos contra la gripe se benefician significativamente. Al participar activamente en las iniciativas gubernamentales, estas empresas obtienen acceso a contratos lucrativos y oportunidades de adquisición para el suministro de vacunas a los programas nacionales de inmunización. Además, la participación en los programas de vacunación permite a las empresas farmacéuticas mostrar la eficacia y la seguridad de sus medicamentos contra la gripe, lo que mejora su reputación y visibilidad en el mercado. A medida que los gobiernos priorizan cada vez más la preparación contra los brotes de gripe estacional y las posibles pandemias, la demanda de vacunas y terapias innovadoras sigue aumentando. Las empresas que colaboran activamente con las agencias gubernamentales, proporcionan cadenas de suministro confiables y demuestran compromiso con los objetivos de salud pública están preparadas para capitalizar esta creciente demanda del mercado. Al aprovechar las asociaciones gubernamentales y participar activamente en los programas de vacunación, las empresas farmacéuticas no solo pueden contribuir a la lucha mundial contra la gripe, sino también impulsar el crecimiento y la expansión sostenibles dentro del mercado de medicamentos contra la gripe. Los gobiernos también se centran en las campañas, enfatizando la importancia de la vacunación y la adherencia a los regímenes de tratamiento prescritos, lo que impulsa aún más el crecimiento del mercado.
Por ejemplo,
- In December 2023, according to the article published by Centers for Disease Control and Prevention, U.S government start National Influenza Vaccination Week (NIVW) which is an annual observance in December to remind everyone 6 months and older that there’s still time to get vaccinated against flu. This annual event, held in December, aims to raise awareness about the importance of influenza vaccination and encourage more people, particularly those in high-risk groups, to get vaccinated. NIVW also provides resources and tools to healthcare providers to facilitate vaccination efforts across the country.
- In July 2023, according to the article published by Department of Health and Aged Care , the Australian government launched the National Immunization Program (NIP) to enhance access to influenza vaccines for eligible populations. The program provides free influenza vaccines to vulnerable groups, including children aged 6 months to less than 5 years, pregnant women, Aboriginal and Torres Strait Islander people, and individuals aged 65 years and older. This initiative aims to reduce the burden of influenza and its associated complications on public health.
- In March 2024, according to the article published by Ministry of Health & Family Welfare, Universal Immunization Program (UIP) (ongoing) launched in 1985, aims to provide vaccination against preventable diseases to all children across the country. In recent years, India has expanded its immunization efforts to include influenza vaccination for high-risk groups, such as healthcare workers, elderly individuals, and those with underlying health conditions. These vaccines, often available in both trivalent and quadrivalent formulations include antiviral which help safeguard against various strains of influenza, including Influenza type B. By incorporating these vaccines into the UIP, India aims to reduce the burden of influenza-related illness and contribute to the overall improvement of public health outcomes across the nation.
In conclusion, the increasing involvement in various government initiatives and vaccination programs significantly contributes to the overall revenue growth of pharmaceutical companies specializing in influenza drugs. By aligning with governmental priorities and actively participating in immunization strategies, these companies gain access to lucrative contracts and procurement opportunities, driving demand for their products. Moreover, engagement in vaccination programs allows pharmaceutical firms to demonstrate the efficacy and safety of their influenza drugs, enhancing their reputation and market visibility, thus attracting more customers globally and expected to act as a driver for market growth
Opportunity
- Integration of Telemedicine and Digital Health Solutions
Telemedicine offers healthcare providers the ability to remotely consult with patients, providing timely assessment and management of influenza symptoms without the need for face-to-face visits. This is particularly beneficial during influenza outbreaks, as it reduces the risk of virus transmission in healthcare settings and improves patient flow management.
Digital health solutions, such as mobile apps and wearable devices, are crucial for monitoring influenza symptoms and ensuring treatment adherence. These tools allow patients to track their symptoms, medication schedules, and overall health status, providing valuable data for remote monitoring by healthcare providers. Additionally, these digital tools empower patients to play a more active role in their healthcare, leading to improved treatment outcomes.
For Instance,
- In April 2022, according to an article published by BioMed Central Ltd, during a telehealth visit for a patient with influenza-like illness, a test threshold of around 25% and a treatment threshold of about 60% has been established. The inclusion of home influenza test outcomes decreased uncertainty and markedly reduced the necessity for in-person visits.
- In February 2022, according to an article published by MDPI, maternal influenza vaccination reduces illness and death in pregnant women and lowers risks for babies. A study on the "Influenza Vaccination Reminder Application" found it improved pregnant women's knowledge, attitudes, and intention to get vaccinated. The app, accessible on smartphones, offers valuable information, promoting vaccination and preventing missed opportunities.
- In September 2021, according to an article published by Johnson & Johnson Services, Inc., Cue Health is a digitally connected health monitoring system that begins with a rapid at-home diagnostic test. This test is linked to a telemedicine provider who can prescribe medication based on the test result. Originally focused on influenza, Cue Health is a rapid point-of-care diagnostics company.
- In October 2020, according to an article published by National Institutes of Health, Oseltamivir can reduce the duration of influenza symptoms, but it must be given within 48 hours of symptom onset. However, in primary care settings, only 20% of patients receive oseltamivir. This low rate is often due to false negative test results and patients seeking treatment after the 48-hour window. Direct-to-consumer (DTC) telemedicine could address these challenges by connecting patients with physicians 24 hours a day. This approach could help overcome delays in treatment and avoid exposing others to infection.
In conclusion, the integration of telemedicine and digital health in influenza diagnosis and treatment enhances healthcare accessibility, improves patient convenience, and enables more personalized and timely care. This integration also creates new opportunities for drug delivery and monitoring, enabling remote monitoring of patients' health status and facilitating the delivery of antiviral medications to remote or underserved areas. Overall, this integration represents a significant opportunity for advancing healthcare delivery in the management of influenza and other infectious diseases.
Restraint/Challenge
- Adverse Effect of Anti-Influenza Drugs
Influenza drugs, despite their efficacy in managing influenza infections, can act as a restraint for market growth due to the potential occurrence of adverse side effects. While common side effects like nausea, vomiting, headache, and diarrhea are generally tolerable, more severe reactions such as allergic responses, skin rash, or respiratory distress can deter patients from continued use. The rare occurrence of neuropsychiatric events, such as hallucinations or abnormal behavior, associated with antiviral medications like oseltamivir (Tamiflu) and zanamivir (Relenza), particularly in younger patients, raises concerns among healthcare providers and patients alike. These adverse effects may lead to hesitancy in prescribing or using influenza drugs, impacting market demand and growth.
For instance,
- In Feb 2020, according to the article published by NCBI, the adverse effects of neuraminidase inhibitors (NAIs) exhibit age-dependent variability, as observed in the findings reported by WebMD. In younger patients administered oseltamivir, a disproportionality in adverse reactions such as vomiting and hallucinations was detected. Conversely, older patients receiving peramivir exhibited adverse events including abnormal hepatic function, cardiac failure, shock, and cardio-arrest. Psychiatric disorders were most prevalent across both younger and older age groups, while gastrointestinal disorders predominated in adults administered oseltamivir
- In April 2024, according to the article published by Mayo Foundation for Medical Education and Research (MFMER), symptom such as nausea, puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue, severe headache, skin rash, stiff neck and/or back, and sudden numbness and weakness in the arms and legs, can be associated with severe adverse reactions to certain drugs and supplements used to treat influenza. While influenza medications like oseltamivir (Tamiflu) and zanamivir (Relenza) are generally well-tolerated, in rare cases, individuals may experience severe allergic reactions or adverse effects.
In conclusion, while influenza drugs are effective in managing influenza infections, the occurrence of adverse side effects acts as a significant restraint on market growth. Common side effects such as nausea, vomiting, and headache, along with more severe reactions like allergic responses and neuropsychiatric events, can deter patients from using these medications. Concerns about safety and tolerability may lead to hesitancy among healthcare providers in prescribing influenza drugs and decrease patient adherence to treatment regimens.
Recent Developments
- In November 2023, AstraZeneca has announced a partnership and investment deal with Cellectis, a clinical-stage biotech company, to speed up the development of new therapies in areas with significant unmet medical needs such as oncology, immunology, and rare diseases. This collaboration will allow AstraZeneca to utilize Cellectis' gene editing technologies and manufacturing capabilities to create innovative cell and gene therapy products, enhancing AstraZeneca's portfolio in this field.
- In June 2023, GSK plc. and BELLUS Health Inc. announced today that GSK has finalized the acquisition of BELLUS, a biopharmaceutical company dedicated to improving the lives of patients with refractory chronic cough (RCC). This acquisition will enhance GSK's portfolio by adding BELLUS's expertise in refractory chronic cough (RCC) treatment, strengthening its position in addressing unmet medical needs in this area.
- In June 2023, Sanofi hosted a Vaccines Investor Event focusing on its pipeline, showcasing how its strategy is backed by vaccines R&D. The company aims for sustained growth in the vaccines business through core franchises in influenza, meningitis, and pediatric vaccines, along with a best-in-class RSV franchise to protect infants, toddlers, and older adults. This event will help Sanofi highlight its strategic focus on vaccines R&D and core franchises, showcasing its potential for sustained growth in the vaccines business.
- In November 2022, CSL has announced that its subsidiary, CSL Seqirus, has signed a collaboration and licensing agreement with Arcturus Therapeutics Holdings Inc to utilize their advanced self-amplifying mRNA (sa-mRNA) vaccine platform technology in the later stages of development. This collaboration will enable CSL Seqirus to leverage Arcturus Therapeutics' advanced sa-mRNA vaccine platform technology, potentially enhancing CSL's vaccine development capabilities.
- In May 2022, GSK plc announced a definitive agreement to acquire Affinivax, Inc., a clinical-stage biopharmaceutical company. The acquisition involves a $2.1 billion upfront payment and up to $1.2 billion in potential development milestones. This acquisition will strengthen GSK's vaccine pipeline by incorporating Affinivax's innovative MAPS technology, enhancing its ability to develop next-generation vaccines for various infectious diseases.
- In January 2022, Natco Pharma Limited has recently announced the signing of a non-exclusive licensing agreement with the Medicines Patent Pool (MPP) in Switzerland. The MPP had previously acquired the license from Merck Sharp & Dohme Corp. (MSD) in the USA for the same purpose. This agreement with the Medicines Patent Pool will enable Natco Pharma Limited to expand its access to important medicines and enhance its ability to provide affordable healthcare solutions to a broader population.
- In January 2022, NATCO Pharma Inc. USA, a wholly owned subsidiary of NATCO Pharma Limited, has finalized the acquisition of Dash Pharmaceuticals LLC, based in New Jersey. Following this transaction, Dash will operate as a 100% wholly owned subsidiary of NATCO Pharma Inc. and a step-down subsidiary of NATCO.
Global Influenza Drug Market Scope
The global Influenza drug market is segmented into six notable segments based on type, treatment, route of administration, age, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.
Type
- Influenza A
- Influenza B
- Influenza C
On the basis of type, the market is segmented into Influenza A, Influenza B and Influenza C.
Treatment
- Vaccines
- Drugs
On the basis of treatment, the market is segmented into vaccines and drugs.
Route of Administration
- Oral
- Intramuscular
- Intradermal
- Intranasal
- Intravenous
On the basis of route of administration, the market is segmented into oral, intramuscular, intradermal, intranasal, and intravenous.
Age
- Pediatrics
- Adults
On the basis of age, the market is segmented into pediatrics and adults.
End User
- Hospitals
- Homecare
On the basis of end user, the market is segmented into hospitals and homecare.
Distribution Channel
- Direct Tender
- Retail Sales
On the basis of distribution channel, the market is segmented into direct tenders and retail sales.
Global Influenza Drug Market Regional Analysis/Insights
The global Influenza drug market is analyzed, and market size insights and trends are provided by based on type, treatment, route of administration, age, end user, and distribution channel as referenced above.
The countries covered in this market report are U.S., Canada, Mexico, Germany, France, U.K., Germany, Spain, Italy, France, Russia, Netherlands, Turkey, Switzerland, Belgium, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Indonesia, Philippines, Malaysia, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel and Rest of Middle East and Africa.
North America is expected to dominate the market due to due to its advanced healthcare infrastructure, well-equipped hospitals, clinics, and home care centers, which ensures quality care for patients.
Se espera que Estados Unidos domine el mercado de América del Norte debido a su alta prevalencia de casos de gripe, su sólida infraestructura sanitaria, su robusta industria farmacéutica y su elevada conciencia pública sobre la prevención de la gripe. Se espera que el Reino Unido domine el mercado de Europa debido a su avanzado sistema sanitario, su alta cobertura de vacunación y sus iniciativas gubernamentales proactivas para combatir los brotes de gripe. Se espera que Japón domine el mercado de Asia y el Pacífico debido a sus elevados estándares sanitarios, sus avanzadas capacidades de investigación y desarrollo y su gran población de ancianos, que es especialmente vulnerable a la gripe.
La sección de países del informe también proporciona factores de impacto de mercado individuales y cambios en la regulación del mercado que afectan las tendencias actuales y futuras del mercado. Los puntos de datos como el análisis de la cadena de valor ascendente y descendente, las tendencias técnicas y el análisis de las cinco fuerzas de Porter, los estudios de casos son algunos de los indicadores utilizados para pronosticar el escenario del mercado para países individuales. Además, la presencia y disponibilidad de marcas globales y sus desafíos enfrentados debido a la competencia grande o escasa de las marcas locales y nacionales, el impacto de los aranceles nacionales y las rutas comerciales se consideran al proporcionar un análisis de pronóstico de los datos del país.
Análisis del panorama competitivo y de la cuota de mercado mundial de medicamentos contra la gripe
El panorama competitivo del mercado mundial de medicamentos contra la gripe proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, la presencia global, los sitios e instalaciones de producción, las capacidades de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, la amplitud y variedad de productos y el dominio de las aplicaciones. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de las empresas en el mercado mundial de medicamentos contra la gripe.
Algunos de los principales actores que operan en el mercado mundial de medicamentos contra la gripe son GSK plc., Sanofi SA, CSL, Astrazeneca Plc, F. Hoffmann-La Roche Ltd, Viatris Inc., Abbott, Amneal Pharmaceuticals LLC., AbbVie Inc BioCryst Pharmaceutucals, Inc., Lupin, Zydus Pharmaceuticals, Inc., Macleods Pharmaceuticals Ltd., Viatris Inc., DAIICHI SANKYO COMPANY, LIMITED, Cipla Inc., Shionogi & Co., Ltd., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, NATCO Pharma Limited y Alvogen, entre otros.
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE GLOBAL INFLUENZA DRUG MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S FIVE FORCES MODEL
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 INCREASING PREVALENCE RATE OF INFLUENZA
5.1.2 GOVERNMENT INITIATIVES AND VACCINATION PROGRAMS
5.1.3 ADVANCEMENTS IN MEDICAL RESEARCH AND TECHNOLOGY
5.1.4 CONTINOUS LAUNCHES OF THE NEW DRUGS AND VACCINE
5.2 RESTRAINTS
5.2.1 ADVERSE EFFECT OF ANTI-INFLUENZA DRUGS
5.2.2 COUNTERFEIT OF DRUG IN PHARMACEUTICAL INDUSTRY
5.3 OPPORTUNITIES
5.3.1 INTEGRATION OF TELEMEDICINE AND DIGITAL HEALTH SOLUTIONS
5.3.2 DEVELOPMENT OF COMBINATION THERAPIES
5.3.3 ADVANCING UNIVERSAL VACCINES
5.4 CHALLENGES
5.4.1 EMERGENCE OF DRUG RESISTANT STRAINS
5.4.2 INEFFICIENCY IN THE SUPPLY CHAIN OF VACCINE
6 GLOBAL INFLUENZA DRUG MARKET, BY TYPE
6.1 OVERVIEW
6.2 INFLUENZA A
6.3 INFLUENZA B
6.4 INFLUENZA C
7 GLOBAL INFLUENZA DRUG MARKET, BY TREATMENT
7.1 OVERVIEW
7.2 VACCINES
7.3 DRUGS
8 GLOBAL INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION
8.1 OVERVIEW
8.2 ORAL
8.3 INTRAMUSCULAR
8.4 INTRADERMAL
8.5 INTRANASAL
8.6 INTRAVENOUS
9 GLOBAL INFLUENZA DRUG MARKET, BY AGE
9.1 OVERVIEW
9.2 PEDIATRICS
9.3 ADULTS
10 GLOBAL INFLUENZA DRUG MARKET, BY END USER
10.1 OVERVIEW
10.2 HOSPITALS
10.3 HOMECARE
11 GLOBAL INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL
11.1 OVERVIEW
11.2 DIRECT TENDER
11.3 RETAIL SALES
12 GLOBAL INFLUENZA DRUG MARKET, BY REGION
12.1 OVERVIEW
12.2 NORTH AMERICA
12.2.1 U S
12.2.2 MEXICO
12.2.3 CANADA
12.3 EUROPE
12.3.1 U.K.
12.3.2 GERMANY
12.3.3 SPAIN
12.3.4 ITALY
12.3.5 FRANCE
12.3.6 RUSSIA
12.3.7 NETHERLAND
12.3.8 TURKEY
12.3.9 SWITZERLAND
12.3.10 BELGIUM
12.3.11 REST OF EUROPE
12.4 ASIA-PACIFIC
12.4.1 JAPAN
12.4.2 CHINA
12.4.3 SOUTH KOREA
12.4.4 INDIA
12.4.5 AUSTRALIA
12.4.6 MALAYSIA
12.4.7 THAILAND
12.4.8 INDONESIA
12.4.9 SINGAPORE
12.4.10 PHILIPPINES
12.4.11 REST OF ASIA-PACIFIC
12.5 SOUTH AMERICA
12.5.1 BRAZIL
12.5.2 ARGENTINA
12.5.3 REST OF SOUTH AMERICA
12.6 MIDDLE EAST AND AFRICA
12.6.1 SOUTH AFRICA
12.6.2 U.A.E.
12.6.3 SAUDI ARABIA
12.6.4 EGYPT
12.6.5 ISRAEL
12.6.6 REST OF MIDDLE EAST AND AFRICA
13 GLOBAL INFLUENZA DRUG MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: GLOBAL
13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
13.3 COMPANY SHARE ANALYSIS: EUROPE
13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
14 SWOT ANALYSIS
15 COMPANY PROFILES
15.1 GSK PLC.
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENTS
15.2 SANOFI
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENTS
15.3 CSL
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 COMPANY SHARE ANALYSIS
15.3.4 PRODUCT PORTFOLIO
15.3.5 RECENT DEVELOPMENTS
15.4 ASTRAZENECA
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 COMPANY SHARE ANALYSIS
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENT
15.5 F. HOFFMANN-LA ROCHE LTD.
15.5.1 COMPANY SNAPSHOT
15.5.1 REVENUE ANALYSIS
15.5.2 COMPANY SHARE ANALYSIS
15.5.3 PRODUCT PORTFOLIO
15.5.4 RECENT DEVELOPMENT
15.6 ABBOTT
15.6.1 COMPANY SNAPSHOT
15.6.2 REVENUE ANALYSIS
15.6.3 PRODUCT PORTFOLIO
15.6.4 RECENT DEVELOPMENT
15.7 ABBVIE INC.
15.7.1 COMPANY SNAPSHOT
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 RECENT DEVELOPMENT
15.8 ALVOGEN
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENT
15.9 AMNEAL PHARMACEUTICALS LLC.
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENT
15.1 BIOCRYST PHARMACEUTICALS, INC.
15.10.1 COMPANY SNAPSHOT
15.10.2 REVENUE ANALYSIS
15.10.3 PRODUCT PORTFOLIO
15.10.4 RECENT DEVELOPMENT
15.11 CIPLA INC.
15.11.1 COMPANY SNAPSHOT
15.11.2 REVENUE ANALYSIS
15.11.3 PRODUCT PORTFOLIO
15.11.4 RECENT DEVELOPMENT
15.12 DAIICHI SANKYO COMPANY, LIMITED
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENT
15.13 LUPIN
15.13.1 COMPANY SNAPSHOT
15.13.2 REVENUE ANALYSIS
15.13.3 PRODUCT PORTFOLIO
15.13.4 RECENT DEVELOPMENT
15.14 MACLEODS PHARMACEUTICALS LTD.
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENT
15.15 NATCO PHARMA LIMITED
15.15.1 COMPANY SNAPSHOT
15.15.2 REVENUE ANALYSIS
15.15.3 PRODUCT PORTFOLIO
15.15.4 RECENT DEVELOPMENT
15.16 SHIONOGI & CO., LTD.
15.16.1 COMPANY SNAPSHOT
15.16.2 REVENUE ANALYSIS
15.16.3 PRODUCT PORTFOLIO
15.16.4 RECENT DEVELOPMENT
15.17 TAKEDA PHARMACEUTICAL COMPANY LIMITED
15.17.1 COMPANY SNAPSHOT
15.17.2 REVENUE ANALYSIS
15.17.3 PRODUCT PORTFOLIO
15.17.4 RECENT DEVELOPMENT
15.18 TEVA PHARMACEUTICAL INDUSTRIES LTD.
15.18.1 COMPANY SNAPSHOT
15.18.2 REVENUE ANALYSIS
15.18.3 PRODUCT PORTFOLIO
15.18.4 RECENT DEVELOPMENT
15.19 VIATRIS INC.
15.19.1 COMPANY SNAPSHOT
15.19.2 REVENUE ANALYSIS
15.19.3 PRODUCT PORTFOLIO
15.19.4 RECENT DEVELOPMENT
15.2 ZYDUS PHARMACEUTICALS, INC.
15.20.1 COMPANY SNAPSHOT
15.20.2 REVENUE ANALYSIS
15.20.3 PRODUCT PORTFOLIO
15.20.4 RECENT DEVELOPMENTS
16 QUESTIONNAIRE
17 RELATED REPORTS
Lista de Tablas
TABLE 1 GLOBAL INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 2 GLOBAL INFLUENZA A IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 3 GLOBAL INFLUENZA B IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 4 GLOBAL INFLUENZA C IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 5 GLOBAL INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 6 GLOBAL INFLUENZA A IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 7 GLOBAL DRUGS IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 8 GLOBAL VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 9 GLOBAL QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 10 GLOBAL TRIVALENTIN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 11 GLOBAL BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 12 GLOBAL MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 13 GLOBAL VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 14 GLOBAL INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 15 GLOBAL LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 16 GLOBAL DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 17 GLOBAL INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 18 GLOBAL ORAL MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 19 GLOBAL INTRAMUSCULAR IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 20 GLOBAL INTRADERMAL IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 21 GLOBAL INTRANASAL IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 22 GLOBAL INTRAVENOUS IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 23 GLOBAL INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 24 GLOBAL PEDIATRICS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 25 GLOBAL ADULTS IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 26 GLOBAL INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 27 GLOBAL HOSPITALS IN GLOBAL INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 28 GLOBAL HOMECARE IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 29 GLOBAL INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 30 GLOBAL DIRECT TENDER IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 31 GLOBAL RETAIL SALES IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 32 GLOBAL RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 33 GLOBAL INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 34 NORTH AMERICA INFLUENZA DRUG MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 35 NORTH AMERICA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 36 NORTH AMERICA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 37 NORTH AMERICA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 38 NORTH AMERICA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 39 NORTH AMERICA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 40 NORTH AMERICA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 41 NORTH AMERICA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 42 NORTH AMERICA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 43 NORTH AMERICA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 44 NORTH AMERICA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 45 NORTH AMERICA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 46 NORTH AMERICA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 47 NORTH AMERICA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 48 NORTH AMERICA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 49 NORTH AMERICA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 50 NORTH AMERICA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 51 U.S. INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 52 U.S. INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 53 U.S. VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 54 U.S. QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 55 U.S. TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 56 U.S. BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 57 U.S. MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 58 U.S. VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 59 U.S. INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 60 U.S. LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 61 U.S. DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 62 U.S. INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 63 U.S. INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 64 U.S. INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 65 U.S. INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 66 U.S. RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 67 MEXICO INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 68 MEXICO INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 69 MEXICO VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 70 MEXICO QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 71 MEXICO TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 72 MEXICO BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 73 MEXICO MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 74 MEXICO VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 75 MEXICO INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 76 MEXICO LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 77 MEXICO DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 78 MEXICO INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 79 MEXICO INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 80 MEXICO INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 81 MEXICO INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 82 MEXICO RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 83 CANADA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 84 CANADA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 85 CANADA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 86 CANADA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 87 CANADA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 88 CANADA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 89 CANADA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 90 CANADA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 91 CANADA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 92 CANADA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 93 CANADA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 94 CANADA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 95 CANADA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 96 CANADA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 97 CANADA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 98 CANADA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 99 EUROPE INFLUENZA DRUG MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 100 EUROPE INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 101 EUROPE INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 102 EUROPE VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 103 EUROPE QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 104 EUROPE TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 105 EUROPE BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 106 EUROPE MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 107 EUROPE VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 108 EUROPE INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 109 EUROPE LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 110 EUROPE DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 111 EUROPE INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 112 EUROPE INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 113 EUROPE INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 114 EUROPE INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 115 EUROPE RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 116 U.K. INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 117 U.K. INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 118 U.K. VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 119 U.K. QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 120 U.K. TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 121 U.K. BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 122 U.K. MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 123 U.K. VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 124 U.K. INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 125 U.K. LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 126 U.K. DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 127 U.K. INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 128 U.K. INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 129 U.K. INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 130 U.K. INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 131 U.K. RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 132 GERMANY INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 133 GERMANY INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 134 GERMANY VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 135 GERMANY QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 136 GERMANY TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 137 GERMANY BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 138 GERMANY MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 139 GERMANY VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 140 GERMANY INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 141 GERMANY LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 142 GERMANY DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 143 GERMANY INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 144 GERMANY INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 145 GERMANY INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 146 GERMANY INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 147 GERMANY RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 148 SPAIN INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 149 SPAIN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 150 SPAIN VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 151 SPAIN QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 152 SPAIN TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 153 SPAIN BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 154 SPAIN MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 155 SPAIN VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 156 SPAIN INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 157 SPAIN LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 158 SPAIN DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 159 SPAIN INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 160 SPAIN INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 161 SPAIN INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 162 SPAIN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 163 SPAIN RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 164 ITALY INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 165 ITALY INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 166 ITALY VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 167 ITALY QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 168 ITALY TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 169 ITALY BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 170 ITALY MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 171 ITALY VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 172 ITALY INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 173 ITALY LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 174 ITALY DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 175 ITALY INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 176 ITALY INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 177 ITALY INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 178 ITALY INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 179 ITALY RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 180 FRANCE INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 181 FRANCE INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 182 FRANCE VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 183 FRANCE QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 184 FRANCE TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 185 FRANCE BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 186 FRANCE MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 187 FRANCE VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 188 FRANCE INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 189 FRANCE LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 190 FRANCE DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 191 FRANCE INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 192 FRANCE INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 193 FRANCE INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 194 FRANCE INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 195 FRANCE RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 196 RUSSIA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 197 RUSSIA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 198 RUSSIA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 199 RUSSIA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 200 RUSSIA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 201 RUSSIA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 202 RUSSIA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 203 RUSSIA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 204 RUSSIA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 205 RUSSIA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 206 RUSSIA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 207 RUSSIA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 208 RUSSIA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 209 RUSSIA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 210 RUSSIA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 211 RUSSIA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 212 NETHERLANDS INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 213 NETHERLANDS INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 214 NETHERLANDS VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 215 NETHERLANDS QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 216 NETHERLANDS TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 217 NETHERLANDS BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 218 NETHERLANDS MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 219 NETHERLANDS VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 220 NETHERLANDS INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 221 NETHERLANDS LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 222 NETHERLANDS DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 223 NETHERLANDS INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 224 NETHERLANDS INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 225 NETHERLANDS INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 226 NETHERLANDS INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 227 NETHERLANDS RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 228 TURKEY INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 229 TURKEY INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 230 TURKEY VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 231 TURKEY QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 232 TURKEY TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 233 TURKEY BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 234 TURKEY MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 235 TURKEY VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 236 TURKEY INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 237 TURKEY LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 238 TURKEY DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 239 TURKEY INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 240 TURKEY INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 241 TURKEY INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 242 TURKEY INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 243 TURKEY RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 244 SWITZERLAND INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 245 SWITZERLAND INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 246 SWITZERLAND VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 247 SWITZERLAND QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 248 SWITZERLAND TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 249 SWITZERLAND BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 250 SWITZERLAND MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 251 SWITZERLAND VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 252 SWITZERLAND INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 253 SWITZERLAND LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 254 SWITZERLAND DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 255 SWITZERLAND INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 256 SWITZERLAND INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 257 SWITZERLAND INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 258 SWITZERLAND INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 259 SWITZERLAND RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 260 BELGIUM INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 261 BELGIUM INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 262 BELGIUM VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 263 BELGIUM QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 264 BELGIUM TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 265 BELGIUM BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 266 BELGIUM MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 267 BELGIUM VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 268 BELGIUM INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 269 BELGIUM LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 270 BELGIUM DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 271 BELGIUM INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 272 BELGIUM INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 273 BELGIUM INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 274 BELGIUM INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 275 BELGIUM RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 276 REST OF EUROPE INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 277 ASIA-PACIFIC INFLUENZA DRUG MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 278 ASIA-PACIFIC INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 279 ASIA-PACIFIC INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 280 ASIA-PACIFIC VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 281 ASIA-PACIFIC QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 282 ASIA-PACIFIC TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 283 ASIA-PACIFIC BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 284 ASIA-PACIFIC MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 285 ASIA-PACIFIC VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 286 ASIA-PACIFIC INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 287 ASIA-PACIFIC LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 288 ASIA-PACIFIC DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 289 ASIA-PACIFIC INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 290 ASIA-PACIFIC INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 291 ASIA-PACIFIC INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 292 ASIA-PACIFIC INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 293 ASIA-PACIFIC RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 294 JAPAN INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 295 JAPAN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 296 JAPAN VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 297 JAPAN QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 298 JAPAN TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 299 JAPAN BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 300 JAPAN MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 301 JAPAN VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 302 JAPAN INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 303 JAPAN LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 304 JAPAN DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 305 JAPAN INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 306 JAPAN INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 307 JAPAN INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 308 JAPAN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 309 JAPAN RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 310 CHINA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 311 CHINA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 312 CHINA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 313 CHINA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 314 CHINA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 315 CHINA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 316 CHINA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 317 CHINA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 318 CHINA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 319 CHINA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 320 CHINA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 321 CHINA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 322 CHINA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 323 CHINA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 324 CHINA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 325 CHINA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 326 SOUTH KOREA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 327 SOUTH KOREA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 328 SOUTH KOREA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 329 SOUTH KOREA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 330 SOUTH KOREA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 331 SOUTH KOREA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 332 SOUTH KOREA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 333 SOUTH KOREA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 334 SOUTH KOREA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 335 SOUTH KOREA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 336 SOUTH KOREA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 337 SOUTH KOREA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 338 SOUTH KOREA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 339 SOUTH KOREA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 340 SOUTH KOREA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 341 SOUTH KOREA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 342 INDIA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 343 INDIA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 344 INDIA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 345 INDIA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 346 INDIA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 347 INDIA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 348 INDIA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 349 INDIA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 350 INDIA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 351 INDIA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 352 INDIA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 353 INDIA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 354 INDIA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 355 INDIA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 356 INDIA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 357 INDIA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 358 AUSTRALIA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 359 AUSTRALIA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 360 AUSTRALIA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 361 AUSTRALIA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 362 AUSTRALIA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 363 AUSTRALIA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 364 AUSTRALIA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 365 AUSTRALIA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 366 AUSTRALIA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 367 AUSTRALIA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 368 AUSTRALIA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 369 AUSTRALIA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 370 AUSTRALIA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 371 AUSTRALIA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 372 AUSTRALIA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 373 AUSTRALIA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 374 MALAYSIA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 375 MALAYSIA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 376 MALAYSIA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 377 MALAYSIA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 378 MALAYSIA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 379 MALAYSIA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 380 MALAYSIA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 381 MALAYSIA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 382 MALAYSIA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 383 MALAYSIA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 384 MALAYSIA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 385 MALAYSIA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 386 MALAYSIA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 387 MALAYSIA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 388 MALAYSIA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 389 MALAYSIA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 390 THAILAND INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 391 THAILAND INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 392 THAILAND VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 393 THAILAND QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 394 THAILAND TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 395 THAILAND BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 396 THAILAND MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 397 THAILAND VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 398 THAILAND INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 399 THAILAND LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 400 THAILAND DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 401 THAILAND INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 402 THAILAND INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 403 THAILAND INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 404 THAILAND INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 405 THAILAND RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 406 INDONESIA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 407 INDONESIA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 408 INDONESIA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 409 INDONESIA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 410 INDONESIA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 411 INDONESIA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 412 INDONESIA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 413 INDONESIA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 414 INDONESIA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 415 INDONESIA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 416 INDONESIA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 417 INDONESIA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 418 INDONESIA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 419 INDONESIA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 420 INDONESIA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 421 INDONESIA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 422 SINGAPORE INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 423 SINGAPORE INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 424 SINGAPORE VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 425 SINGAPORE QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 426 SINGAPORE TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 427 SINGAPORE BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 428 SINGAPORE MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 429 SINGAPORE VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 430 SINGAPORE INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 431 SINGAPORE LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 432 SINGAPORE DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 433 SINGAPORE INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 434 SINGAPORE INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 435 SINGAPORE INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 436 SINGAPORE INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 437 SINGAPORE RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 438 PHILIPPINES INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 439 PHILIPPINES INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 440 PHILIPPINES VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 441 PHILIPPINES QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 442 PHILIPPINES TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 443 PHILIPPINES BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 444 PHILIPPINES MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 445 PHILIPPINES VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 446 PHILIPPINES INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 447 PHILIPPINES LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 448 PHILIPPINES DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 449 PHILIPPINES INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 450 PHILIPPINES INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 451 PHILIPPINES INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 452 PHILIPPINES INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 453 PHILIPPINES RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 454 REST OF ASIA-PACIFIC INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 455 SOUTH AMERICA INFLUENZA DRUG MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 456 SOUTH AMERICA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 457 SOUTH AMERICA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 458 SOUTH AMERICA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 459 SOUTH AMERICA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 460 SOUTH AMERICA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 461 SOUTH AMERICA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 462 SOUTH AMERICA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 463 SOUTH AMERICA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 464 SOUTH AMERICA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 465 SOUTH AMERICA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 466 SOUTH AMERICA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 467 SOUTH AMERICA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 468 SOUTH AMERICA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 469 SOUTH AMERICA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 470 SOUTH AMERICA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 471 SOUTH AMERICA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 472 BRAZIL INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 473 BRAZIL INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 474 BRAZIL VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 475 BRAZIL QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 476 BRAZIL TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 477 BRAZIL BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 478 BRAZIL MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 479 BRAZIL VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 480 BRAZIL INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 481 BRAZIL LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 482 BRAZIL DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 483 BRAZIL INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 484 BRAZIL INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 485 BRAZIL INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 486 BRAZIL INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 487 BRAZIL RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 488 ARGENTINA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 489 ARGENTINA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 490 ARGENTINA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 491 ARGENTINA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 492 ARGENTINA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 493 ARGENTINA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 494 ARGENTINA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 495 ARGENTINA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 496 ARGENTINA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 497 ARGENTINA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 498 ARGENTINA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 499 ARGENTINA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 500 ARGENTINA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 501 ARGENTINA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 502 ARGENTINA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 503 ARGENTINA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 504 REST OF SOUTH AMERICA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 505 MIDDLE EAST AND AFRICA INFLUENZA DRUG MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 506 MIDDLE EAST AND AFRICA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 507 MIDDLE EAST AND AFRICA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 508 MIDDLE EAST AND AFRICA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 509 MIDDLE EAST AND AFRICA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 510 MIDDLE EAST AND AFRICA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 511 MIDDLE EAST AND AFRICA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 512 MIDDLE EAST AND AFRICA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 513 MIDDLE EAST AND AFRICA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 514 MIDDLE EAST AND AFRICA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 515 MIDDLE EAST AND AFRICA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 516 MIDDLE EAST AND AFRICA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 517 MIDDLE EAST AND AFRICA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 518 MIDDLE EAST AND AFRICA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 519 MIDDLE EAST AND AFRICA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 520 MIDDLE EAST AND AFRICA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 521 MIDDLE EAST AND AFRICA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 522 SOUTH AFRICA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 523 SOUTH AFRICA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 524 SOUTH AFRICA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 525 SOUTH AFRICA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 526 SOUTH AFRICA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 527 SOUTH AFRICA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 528 SOUTH AFRICA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 529 SOUTH AFRICA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 530 SOUTH AFRICA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 531 SOUTH AFRICA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 532 SOUTH AFRICA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 533 SOUTH AFRICA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 534 SOUTH AFRICA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 535 SOUTH AFRICA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 536 SOUTH AFRICA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 537 SOUTH AFRICA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 538 U.A.E. INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 539 U.A.E. INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 540 U.A.E. VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 541 U.A.E. QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 542 U.A.E. TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 543 U.A.E. BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 544 U.A.E. MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 545 U.A.E. VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 546 U.A.E. INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 547 U.A.E. LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 548 U.A.E. DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 549 U.A.E. INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 550 U.A.E. INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 551 U.A.E. INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 552 U.A.E. INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 553 U.A.E. RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 554 SAUDI ARABIA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 555 SAUDI ARABIA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 556 SAUDI ARABIA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 557 SAUDI ARABIA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 558 SAUDI ARABIA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 559 SAUDI ARABIA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 560 SAUDI ARABIA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 561 SAUDI ARABIA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 562 SAUDI ARABIA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 563 SAUDI ARABIA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 564 SAUDI ARABIA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 565 SAUDI ARABIA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 566 SAUDI ARABIA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 567 SAUDI ARABIA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 568 SAUDI ARABIA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 569 SAUDI ARABIA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 570 EGYPT INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 571 EGYPT INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 572 EGYPT VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 573 EGYPT QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 574 EGYPT TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 575 EGYPT BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 576 EGYPT MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 577 EGYPT VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 578 EGYPT INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 579 EGYPT LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 580 EGYPT DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 581 EGYPT INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 582 EGYPT INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 583 EGYPT INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 584 EGYPT INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 585 EGYPT RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 586 ISRAEL INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 587 ISRAEL INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 588 ISRAEL VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 589 ISRAEL QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 590 ISRAEL TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 591 ISRAEL BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 592 ISRAEL MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 593 ISRAEL VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 594 ISRAEL INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 595 ISRAEL LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 596 ISRAEL DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 597 ISRAEL INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 598 ISRAEL INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 599 ISRAEL INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 600 ISRAEL INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 601 ISRAEL RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 602 REST OF MIDDLE EAST AND AFRICA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
Lista de figuras
FIGURE 1 GLOBAL INFLUENZA DRUG MARKET: SEGMENTATION
FIGURE 2 GLOBAL INFLUENZA DRUG MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL INFLUENZA DRUG MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL INFLUENZA DRUG MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL INFLUENZA DRUG MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL INFLUENZA DRUG MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL INFLUENZA DRUG MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 GLOBAL INFLUENZA DRUG MARKET: DBMR MARKET POSITION GRID
FIGURE 9 GLOBAL INFLUENZA DRUG MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 GLOBAL INFLUENZA DRUG MARKET: SEGMENTATION
FIGURE 11 GOVERNMENT INITIATIVES AND VACCINATION PROGRAMS IS DRIVING THE GROWTH OF THE GLOBAL INFLUENZA DRUG MARKET FROM 2024 TO 2031
FIGURE 12 THE INFLUENZA A SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL INFLUENZA DRUG MARKET IN 2024 AND 2031
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL INFLUENZA DRUG MARKET AND ALSO NORTH AMERICA IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING REGION FOR INFLUENZA DRUG MARKET MANUFACTURERS IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL INFLUENZA DRUGS MARKET
FIGURE 16 GLOBAL INFLUENZA DRUG MARKET: BY TYPE, 2023
FIGURE 17 GLOBAL INFLUENZA DRUG MARKET: BY TYPE, 2024-2031 (USD THOUSAND)
FIGURE 18 GLOBAL INFLUENZA DRUG MARKET: BY TYPE, CAGR (2024-2031)
FIGURE 19 GLOBAL INFLUENZA DRUG MARKET: BY TYPE, LIFELINE CURVE
FIGURE 20 GLOBAL INFLUENZA DRUG MARKET: BY TREATMENT, 2023
FIGURE 21 GLOBAL INFLUENZA DRUG MARKET: BY TREATMENT, 2024-2031 (USD THOUSAND)
FIGURE 22 GLOBAL INFLUENZA DRUG MARKET: BY CAGR (2024-2031)
FIGURE 23 GLOBAL INFLUENZA DRUG MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 24 GLOBAL INFLUENZA DRUG MARKET : BY ROUTE OF ADMINISTRATION, 2023
FIGURE 25 GLOBAL INFLUENZA DRUG MARKET : BY ROUTE OF ADMINISTRATION, 2024-2031 (USD THOUSAND)
FIGURE 26 GLOBAL INFLUENZA DRUG MARKET : BY ROUTE OF ADMINISTRATION, CAGR (2024-2031)
FIGURE 27 GLOBAL INFLUENZA DRUG MARKET : BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 28 GLOBAL INFLUENZA DRUG MARKET : BY AGE, 2023
FIGURE 29 GLOBAL INFLUENZA DRUG MARKET : BY AGE, 2024-2031 (USD THOUSAND)
FIGURE 30 GLOBAL INFLUENZA DRUG MARKET : BY AGE, CAGR (2024-2031)
FIGURE 31 GLOBAL INFLUENZA DRUG MARKET : BY AGE, LIFELINE CURVE
FIGURE 32 GLOBAL INFLUENZA DRUG MARKET : BY END USER, 2023
FIGURE 33 GLOBAL INFLUENZA DRUG MARKET : BY END USER, 2024-2031 (USD THOUSAND)
FIGURE 34 GLOBAL INFLUENZA DRUG MARKET : BY END USER, CAGR (2024-2031)
FIGURE 35 GLOBAL INFLUENZA DRUG MARKET : BY END USER, LIFELINE CURVE
FIGURE 36 GLOBAL INFLUENZA DRUG MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD THOUSAND)
FIGURE 37 GLOBAL INFLUENZA DRUG MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 38 GLOBAL INFLUENZA DRUG MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 39 GLOBAL INFLUENZA DRUG MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 40 GLOBAL INFLUENZA DRUG MARKET: SNAPSHOT (2023)
FIGURE 41 GLOBAL INFLUENZA DRUG MARKET: COMPANY SHARE 2023 (%)
FIGURE 42 NORTH AMERICA INFLUENZA DRUG MARKET: COMPANY SHARE 2023 (%)
FIGURE 43 EUROPE INFLUENZA DRUG MARKET: COMPANY SHARE 2023 (%)
FIGURE 44 AISA-PACIFIC INFLUENZA DRUG MARKET: COMPANY SHARE 2023 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
